基础医学与临床 ›› 2024, Vol. 44 ›› Issue (3): 374-378.doi: 10.16352/j.issn.1001-6325.2024.03.0374

• 临床研究 • 上一篇    下一篇

99mTc-HYNIC-TOC显像和131I-MIBG显像在嗜铬细胞瘤和副神经节瘤中的诊断价值

王宇1,2, 童安莉1*, 周玥1, 张文倩1,2, 崔云英1, 景红丽1*, 李玉秀1   

  1. 1.中国医学科学院 北京协和医学院 北京协和医院 内分泌科 国家卫生健康委员会内分泌重点实验室;3.核医学科,北京100730;
    2.河北北方学院 研究生学院,河北张家口 075000
  • 收稿日期:2023-11-29 修回日期:2023-12-26 出版日期:2024-03-05 发布日期:2024-02-22
  • 通讯作者: *:tonganli@hotmail.com;annsmile1976@sina.com
  • 基金资助:
    国家重点研发计划(2021YFC2501600,2021YFC2501603);中央高水平医院临床科研业务费(2022-PUMCH-C-028);中国医学科学院医学与健康科技创新工程(2021-I2M-C&T-B-002)

Evaluation of 99mTc-HYNIC-TOC and 131I-MIBG imaging in diagnosis of pheochromocytoma and paraganglioma

WANG Yu1,2, TONG Anli1*, ZHOU Yue1, ZHANG Wenqian1,2, CUI Yunying1, JING Hongli3* , LI Yuxiu1   

  1. 1. Department of Endocrinology, Key Laboratory of Endocrinology of National Health Commission;3. Department of Nuclear Medicine, Peking Union Medical College Hospital, CAMS & PUMC, Beijing 100730;
    2. Graduate School, Hebei North University, Zhangjiakou 075000, China
  • Received:2023-11-29 Revised:2023-12-26 Online:2024-03-05 Published:2024-02-22
  • Contact: *:tonganli@hotmail.com;annsmile1976@sina.com

摘要: 目的 探讨99mTc标记肼基烟酰胺奥曲肽类似物(99mTc-HYNIC-TOC)显像与131I-间碘苄胍 (131I-MIBG)肾上腺髓质显像对嗜铬细胞瘤和副神经节瘤(PPGL)的临床诊断价值。方法 回顾性研究359例经手术病理确诊、临床资料完整的PPGL患者的临床资料,分析99mTc-HYNIC-TOC生长抑素受体显像与131I-MIBG肾上腺髓质显像的诊断敏感性及影响因素。结果 319例行99mTc-HYNIC-TOC生长抑素受体显像,病灶检出阳性184例,诊断敏感性为57.7%;279例行131I-MIBG肾上腺髓质显像,病灶检出阳性232例,诊断敏感性为83.2%,原发灶位于肾上腺、腹膜后、头颈部、心脏及纵膈、盆腔及膀胱部位的99mTc-HYNIC-TOC生长抑素受体显像敏感性分别为53.3%、62.5%、95.0%、66.7%、50.0%和11.0%,131I-MIBG肾上腺髓质显像敏感性分别86.7%、88.5%、45.4%、50.0%、75.0%和33.3%。不同遗传背景[包括琥珀酸脱氢酶(SDH)、希佩尔-林道(VHL)及RET原癌基因(RET)基因突变]的PPGL患者中,两种方法诊断PPGL的敏感性差异无统计学意义(P>0.05)。肿瘤最大径的中位数为4.4(3.0,6.1)cm。99mTc-HYNIC-TOC生长抑素受体显像和131I-MIBG 肾上腺髓质显像对较大肿瘤组(≥4.4 cm)的诊断敏感性均显著高于较小肿瘤组(<4.4 cm)(64.0% vs. 51.3%;92.3% vs.74.1%)(P<0.01);19例患者(占5.3%)的肿瘤对这两种显像方法均不摄取。结论 本研究为迄今中国最大PPGL队列的99mTc-HYNIC-TOC生长抑素受体显像及131I-MIBG肾上腺髓质显像的研究。总体而言,131I-MIBG肾上腺髓质显像敏感性较99mTc-HYNIC-TOC生长抑素受体显像高,但对部分部位的肿瘤,如头颈副神经节瘤,后者有明显优势,两者有互补性,临床中需要结合患者的特点进行选用。

关键词: 嗜铬细胞瘤, 副神经节瘤, 99mTc-HYNIC-TOC生长抑素受体显像, 131I-MIBG显像, 诊断敏感性

Abstract: Objective To evaluate 99mTc-HYNIC-TOC somatostatin receptor and 131I-MIBG imaging in clinical diag- nostic of pheochromocytoma and paraganglioma (PPGL). Methods This was a retrospective study.359 PPGL patients diagnosed by pathology microscopy were included. The diagnostic sensitivity and influencing factors on 99mTc-HYNIC-TOC somatostatin receptor and 131I-MIBG imaging were analyzed. Results The positive rate of 99mTc-HYNIC-TOC somatostatin receptor scintigraphy was 57.7%(184/319)and 131I-MIBG imaging was 83.2%(232/279). The positive rates of 99mTc-HYNIC-TOC somatostatin receptor imaging in the adrenal glands, retroperitoneum, head and neck, heart and mediastinum, pelvis and bladder were 53.3%, 62.5%, 95.0%, 66.7%, 50.0% and 11.0% respectively and the positive rates of 131I-MIBG imaging were 86.7%, 88.5%, 45.4%, 50.0% ,75.0% and 33.3% respectively. The positive rate of the two imaging did not showed difference among patients with different genetic backgrounds (SDH,VHL,RET mutations). The median maximum diameter of tumors was 4.4(3.0, 6.1)cm.and the diagnostic sensitivity of somatostatin receptor imaging and 131I-MIBG imaging for larger tumors(≥4.4 cm) was significantly higher than those for the smaller tumor group (<4.4 cm) (64.0% vs. 51.3%; 92.3% vs. 74.1%)(P<0.01). Tumors in 19 patients (5.3%) failed to uptake neither imaging method. Conclusions This is the largest PPGL cohort in China concerning 99mTc-HYNIC-TOC somatostatin receptor imaging and 131I-MIBG imaging. The sensitivity of131I-MIBG imaging is higher than that of 99mTc-HYNIC-TOC somatostatin receptor imaging, but for some tumors, such as head and neck paraganglioma, the latter has obvious advantages. These two imagings technologies are complementary and the choice of them should depend the individual situation of patients.

Key words: pheochromocytoma, paraganglioma, 99mTc-HYNIC-TOC somatostatin receptor imaging, 131I-MIBG imaging, diagnostic sensitivity

中图分类号: